Efficacy of mirabegron for voiding disorders in patient who underwent prostate low-dose-rate brachytherapy

Not Applicable

• Conditions: prostate cancer

• Registration Number: JPRN-UMIN000022613
• Lead Sponsor: ara Medical University Department of Urology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-07-01
• Study Completion: 2018-12-03
• Results First Posted: 2020-10-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Male
• Target Recruitment: 218

Inclusion Criteria

Not provided

Exclusion Criteria

considered unsuitable for the trial by doctors residual urine volume greater than 100 ml Qmax less than 5 ml per second contraindicated to medication with mirabegron history of urinary retention performance of clean intermittent catheterization

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the change from baseline to three months later after brachytherapy in mean volume voided per micturition

Secondary Outcome Measures

Name	Time	Method
the change from baseline to three months later after brachytherapy in IPSS,OABSS, and EPIC the change from baseline to three months later after brachytherapy in maximum urinary flow rate, residual urine volume, and mean number of micturitions per 24 hours.